Last reviewed · How we verify
Henagliflozin 10mg
At a glance
| Generic name | Henagliflozin 10mg |
|---|---|
| Also known as | lifestyle intervention |
| Sponsor | Shandong Provincial Hospital |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- The Effects of Henagliflozin on Glucose Fluctuation and Immunosenescence in Type 2 Diabetes Patients on Insulin Therapy (PHASE4)
- Effects of Henagliflozin on the Brain Function in T2DM Patients With Mild Cognitive Impairment: a Randomized, Parallel Controlled Clinical Trial (NA)
- Effect of Henagliflozin on Renal Outcomes in Non-dialysis Patients With Advanced Chronic Kidney Disease : A Multicenter Prospective, Randomized Controlled Trial（HERO -aCKD） (PHASE4)
- Henagliflozin on Liver Fibrosis in Patients with MASLD and T2DM (PHASE4)
- Henagliflozin's Impact on Prediabetes Remission (PHASE4)
- Efficacy of Henagliflozin for Weight Loss in Obesity Without Diabetes (PHASE4)
- The Effect of Henagliflozin and Metformin on Myocardial Tissue-level Characteristics (NA)
- Henagliflozin Delays the Progress of Diabetic Nephropathy Via Regulates Gut-Renal Axis (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Henagliflozin 10mg CI brief — competitive landscape report
- Henagliflozin 10mg updates RSS · CI watch RSS
- Shandong Provincial Hospital portfolio CI